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Summary and Implications
The primary objective of this study was to determine if
an orally administered concentrated equine serum product
provided in the first hours of life could prevent failure of
passive transfer in foals.  To achieve this objective, ten foals
of Quarter Horse breeding were utilized.  Treated foals were
administered 250 ml of an oral serum product at 1 and 3 h
of age via nasogastric intubation.  These foals were muzzled
to prevent nursing from their dam.  Supplemental milk
replacer (200 ml/feeding) was provided to the treated foals at
6 h and 9 h of age.  Mares of treated foals had their udder
stripped at 1, 3, 6, and 9 h post parturition.  The initial
colostrum collected (200 ml) was fed back to the treated
foals when the muzzle was removed at 12 h of age.  Control
foals were allowed to nurse from their dams ad libitum.
Jugular blood samples were obtained from all foals for
determination of concentrations of plasma IgG.  Plasma IgG
concentrations were higher (p<.05) for treated foals
compared to control foals at 5 h and 48 h of age.  Plasma
IgG concentrations were not different (p>.10) at all other
time periods measured.  All treated foals had plasma IgG
concentrations over 700 mg/dl by 10 h of age, showing that
the oral IgG treatment was effective in preventing failure of
passive transfer in foals.
Introduction
Foals are essentially agammaglobulinemic at birth, and
ingestion of adequate amounts of colostrum is essential to
provide the neonatal foal with passive immunity.  Failure to
obtain adequate passive immunity occurs in 15% or more of
Thoroughbred and Standardbred foals, and results in
increases in morbidity and mortality.
     In an attempt to increase immunoglobulin levels in foals
suffering from partial or complete failure of passive transfer
(FPT), many oral and intravenous equine immunoglobulin
supplements have been developed.  If a foal is less than 24
hour old and FPT is confirmed or suspected based on
history, oral immunoglobulin products can be administered
if no banked equine colostrum is available.
     Bovine colostrum can be offered and results in serum
concentrations of IgG over 1300 mg/dl.  Unfortunately, the
half-life of bovine IgG in the foal is much shorter than
equine IgG (7.4 - 9.4 d  for bovine compared to 26 d for
equine IgG).  Also, the ability of the bovine IgG to detect
and present antigen to the foal’s immune system
successfully has not been fully evaluated.
     Most oral equine immunoglobulin products contain
relatively low IgG levels and fail to increase serum IgG
concentrations above 500 mg/dl.  Therefore, the objective of
this study was to evaluate the adequacy of a concentrated
oral purified equine serum product containing much higher
concentrations of equine IgG (36 g of IgG/dose).
Procedures
Ten foals of Quarter Horse breeding were alternately
assigned to either the treated group or the control group.
The dams of the foals ranged in age from 4 to 21 years.
Treated foals were administered 250 ml of an oral serum
product at 1 h and 3 h of age via nasogastric intubation.
These foals were muzzled to prevent nursing from their
dam.  Supplemental milk replacer1 (200 ml/feeding) was
provided to the treated foals at 6 h and 9 h of age.  Mares
with treated foals had their udders stripped at 1, 3, 6, and 9
h post parturition.  The initial colostrum collected (200 ml)
was fed back to the treated foals when the muzzle was
removed at 12 h of age.  Control foals were allowed to
nurse from their dams ad libitum.  Ten ml jugular blood
samples were collected into tubes using EDTA as the
anticoagulant.  Samples were obtained from all foals (5
treated/5 control) at 1, 3, 5, 7, 9, 10, 11, 12, 24, and 48 h
of age for determination of concentrations of plasma IgG.
     Equine serum was purchased from a closed herd of
horses and the IgG was concentrated to 72% purity and
verified by radial immunodiffusion.  The purification
process involved enriching the IgG through standard
chemical precipitation which resulted in the removal of
albumin.  The spray dried product was balanced with 1%
dextrose and 0.1M glycine and mixed in 250 ml of warm
distilled water prior to feeding.  Each dose contained 36 g
of IgG for a total dose of 72 g (2 doses/treated foal x 36
g/dose).
     Plasma was harvested from all blood samples by
centrifugation and IgG concentrations were determined by
radial immunodiffusion.
     Data were analyzed using the analysis of variance
(ANOVA) procedure of SAS and included foal within
treatment interaction as the error term.  Independent effects
included in the statistical model were birth weight, dam
parity, dam age, and foal sex.  Initial IgG level at 1 h was
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included as a covariable.  Significance was declared as P
values less than 0.05.
Results and Discussion
Average foal weight was 50 kg (S.D. ± 6 kg) for
control foals and 47 kg (S.D. ± 5 kg) for treated foals.
Mean values and ranges for plasma IgG concentrations at all
sampling periods are presented in Table 1.  Plasma IgG
concentrations were higher (p<.05) for treated foals
compared to control foals at 5 h and 48 h of age.  Plasma
IgG concentrations were not different (p>.10) at all other
time periods measured.  All treated foals had plasma IgG
concentrations in excess of 700 mg/dl by 10 h of age.
     Mean pre-suckling colostrum values at 1 h were 14,466
mg/dl for dams of control foals and 11,714 mg/dl for dams
of treated foals.  There was no difference in colostrum IgG
concentration between the two groups of foals.
     There are few viable options for producers within the
first 24 hours after a foal is born to prevent failure of
passive transfer if supplemental colostrum is not available.
The oral equine products currently marketed fail to raise IgG
levels to an adequate level, however, there is some evidence
that they can provide protection against illness.  Intravenous
IgG products not only raise foal serum immunoglobulin
levels, but also have the advantage that they can be
administered to a foal of any age.  Drawbacks to intravenous
IgG products include both the invasive nature of
administration and the risk of adverse systemic reactions.
Typical reactions include tachypnea, tachycardia, shaking,
depression, diarrhea, abdominal discomfort and hyperemic
mucous membranes.  Therefore, oral products provide a safe
alternative for foals from mares with a history of inferior
colostrum quality, foals with a history suggestive of FPT,
or simply as a preventative measure.
     Concentrations of IgG in the control foals were
relatively low.  It is possible that the frequency of sampling
interrupted normal foal behavior and resulted in a decrease
in suckling as one control foal still had an IgG
concentration of zero at 3 h.  If control foal IgG
concentrations had been higher, there may have been
significant differences between the two groups of foals,
however, all treated foals still attained IgG levels above 700
mg/dl and two foals achieved levels greater than 1000
mg/dl.
     Even though foals from this study were allowed to nurse
their dam after 12 h of age, the results show that adequate
plasma IgG levels can be achieved through the routine oral
administration of a concentrated immunoglobulin product
within the first 5 hours after birth.  The increased
concentration of IgG observed in the treated foals can be
attributed to the high concentration of IgG contained in the
serum product administered in this study.
     Plasma IgG values were higher at 48 h in treated foals
compared to control foals; this can be explained by the
administration of dam’s colostrum after the 12 h sample.  It
is also possible that the equilibrium process was altered in
the treated foals by the 12 h colostrum feeding.  It takes
approximately 2-3 d for IgG to reach equilibrium between
the intravascular and extravascular space and this process
may have been delayed in the treated foals by the 12 h
colostrum administration.
Because this is a newly developed product, further
studies are needed to test the efficacy of the product for
prevention of illness in colostrum deprived foals.  The
preliminary results from this trial support the use of this
product for prevention of FPT in newborn foals.
